ICH Meets in Japan

News
Article

The International Conference on Harmonization (ICH) Steering Committee (SC) and its working groups met in Fukuoka, Japan Nov. 6-11, 2010.

The International Conference on Harmonization (ICH) Steering Committee (SC) and its working groups met in Fukuoka, Japan, during Nov. 6–11, 2010. ICH moved to open further technical collaboration with non-ICH regions, reported progress in harmonizing quality and safety initiatives, and examined benefit–risk approaches in pharmacovigilance. 

The ICH SC endorsed opening the ICH technical working groups to qualifying members of the Global Cooperation Group (GCG). The GCG includes representatives from Australia, Brazil, China, Chinese Taipei, India, Russia, South Korea, and Singapore, as well the Asia-Pacific Economic Cooperation, (APEC), the Association of Southeast Asian Nations (ASEAN), Gulf Cooperation Countries (GCC), the Pan American Network on Drug Regulatory Harmonization (PANDRH), and the Southern African Development Community (SADC). “This represents a new level of involvement of the GCG and will provide an opportunity for direct technical contributions to the work of ICH, a more global perspective, and will advance implementation of ICH guidelines,” according to an ICH Nov. 11, 2010, press release.

Progress also was made on the harmonization of pharmacopoeial texts. The Annex 7(R2) on Dissolution Test for the ICH Q4B guideline Evaluation and Recommendation of Pharmacopoeial Text for Use in the ICH Regions reached Step 4. ICH, led by the ICH Quality Implementation Working Group (IWG), also held three regional training workshops on the following ICH guidelines: Q8 Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The IWG will proceed to address remaining technical and regulatory gaps identified through the workshops.

To further facilitate harmonization, two new Expert Working Groups launched discussions on the ICH guidelines, M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk and S10 Photosafety Evaluation.

A pharmacovigilance brainstorming session was held for an overarching discussion on safety-update reporting in view of the Development Safety Update Report, which provides common standards for periodic reporting of safety information for drugs under clinical development, and the Periodic Safety Update Report, which harmonizes the reporting of safety information for marketed drugs. The discussion also considered benefit–risk approaches and current legislative parameters and regional constraints. According to ICH, the participants developed a shared vision of pharmacovigilance for optimizing the life cycle benefit–risk of medicines for the promotion and protection of public health. Further discussion will continue within the ICH framework.

The meeting in Japan marked the 20th anniversary of ICH. In recognition, ICH published a brochure, “The Value & Benefits of ICH to Drug Regulatory Authorities—Advancing Harmonization for Public Health.”

The next ICH Steering Committee and its expert working groups meetings will be held in Cincinnati, Ohio, during June 11–16, 2011.

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content